within Pharmacolibrary.Drugs.ATC.C;

model C07FX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.26,
    Cl             = 1.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009666666666666665,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Propranolol is a non-selective beta-adrenergic blocker used primarily to manage hypertension, angina pectoris, cardiac arrhythmias, and in some cases, migraine prophylaxis and anxiety. The ATC code C07FX01 refers to propranolol and its various fixed-dose combinations with other cardiovascular agents, mainly for hypertension and heart disease. Propranolol remains an approved and widely used medication today.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics of propranolol and its fixed-dose combinations in healthy adults, typical oral dose range. Parameters are given as mean values reported in published reference.</p><h4>References</h4><ol><li><p>Hu, Z, et al., &amp; Zhou, S (2005). Herb-drug interactions: a literature review. <i>Drugs</i> 65(9) 1239–1282. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200565090-00005&quot;>10.2165/00003495-200565090-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15916450/&quot;>https://pubmed.ncbi.nlm.nih.gov/15916450</a></p></li><li><p>McLean, AJ, et al., &amp; Dudley, FJ (1980). Interaction between oral propranolol and hydralazine. <i>Clinical pharmacology and therapeutics</i> 27(6) 726–732. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1980.103&quot;>10.1038/clpt.1980.103</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7379440/&quot;>https://pubmed.ncbi.nlm.nih.gov/7379440</a></p></li><li><p>Hamann, SR, et al., &amp; McAllister, RG (1984). Clinical pharmacokinetics of verapamil. <i>Clinical pharmacokinetics</i> 9(1) 26–41. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198409010-00002&quot;>10.2165/00003088-198409010-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6362951/&quot;>https://pubmed.ncbi.nlm.nih.gov/6362951</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07FX01;
